Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2013, Article ID 250865, 2 pages
Case Report

Zolpidem in Progressive Supranuclear Palsy

Department of Neurology, Apollo Hospitals Dhaka, Basundhara R/A, Dhaka 1229, Bangladesh

Received 15 February 2013; Accepted 16 April 2013

Academic Editors: F. C. Henderson, P. Sandroni, and M. Swash

Copyright © 2013 Sandip K. Dash. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Gerhard, I. Trender-Gerhard, F. Turkheimer, N. P. Quinn, K. P. Bhatia, and D. J. Brooks, “In vivo imaging of microglial activation with [11C]-PK11195 PET progresive supranuclear palsy,” Movement Disorders, vol. 21, no. 1, pp. 89–93, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Levy, M. Ruberg, M. T. Herrero et al., “Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA,” Neurology, vol. 45, no. 1, pp. 127–134, 1995. View at Google Scholar · View at Scopus
  3. A. Daniele, E. Moro, and A. R. Bentivoglio, “Zolpidem in progressive supranuclear palsy,” The New England Journal of Medicine, vol. 341, no. 7, pp. 543–544, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. B. J. Mayer, R. M. Bonelli, G. Niederwieser et al., “Zolpidem in progressive supra nuclear palsy,” European Journal of Neurology, vol. 9, pp. 184–185, 2002. View at Google Scholar
  5. C. Cotter, T. Armytage, and D. Crimmins, “The use of zolpidem in the treatment of progressive supranuclear palsy,” Journal of Clinical Neuroscience, vol. 17, no. 3, pp. 385–386, 2010. View at Publisher · View at Google Scholar · View at Scopus